Stanley Hsia
Endocrinology, Diabetes & Metabolism · Los Angeles, CANPI 1841300647
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $6,326 of the $9,270 with a category attached, or 68.2%. It is spread thinly across 12 manufacturers, the largest accounting for just 18.9%. 2025 is the largest year on record at $4,091, more than ten times the $21 reported in 2019.
Across 81 payments — averaging $114.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Boehringer Ingelheim$2K
- Boehringer Ingelheim International GmbH$1K
- Amgen$1K
- Madrigal Pharmaceuticals$1K
- Kowa Research Institute, Inc.$1K
- plus $876 from 6 others
Across 2,051 payments — averaging $9935.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$11.1M
- Sanofi US Services Inc.$1.9M
- Modernatx, Inc.$1.7M
- Boehringer Ingelheim$1.2M
- AbbVie$804K
- AstraZeneca$688K
- plus $3.1M from 22 others
What the payments were for
- Travel & lodging$6,32668%
- Food & beverage$2,90831%
- Education$360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 11 | $1,750 |
| Boehringer Ingelheim | 13 | $1,655 |
| Boehringer Ingelheim International GmbH | 11 | $1,349 |
| Amgen | 5 | $1,265 |
| Madrigal Pharmaceuticals | 8 | $1,203 |
| Kowa Research Institute, Inc. | 11 | $1,172 |
| Corcept Therapeutics | 5 | $483 |
| Novo Nordisk | 8 | $272 |
| Abbott | 2 | $43 |
| Lilly USA, LLC | 2 | $41 |
| Merck | 1 | $35 |
| Travere Therapeutics, Inc. | 4 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,270 in reported general payments places this provider in the 75th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 25 | $37,119 |
| JardianceEmpagliflozin | 13 | $20,783 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $3,485 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 11 | $914 |
| Levothyroxine Sodium | 16 | $115 |
| Glimepiride | 14 | $96 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $272 | $37,11925 claims |
| Boehringer IngelheimJardiance | $1,655 | $20,78313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Los Angeles
- Anthony HeaneyLos Angeles$588K
- Christian GastelumLos Angeles$321K
- Shlomo MelmedLos Angeles$177K
- Sina TebiLos Angeles$133K
- Glenn BraunsteinLos Angeles$113K
- Laurence KatznelsonLos Angeles$99K
- John CarmichaelLos Angeles$90K
- Peter ButlerLos Angeles$58K
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.